BPA Biosante Pharmaceuticals

First Transdermal Testosterone Gel to Significantly Increase Sexual Activity In Surgically Menopausal Women BioSante's LibiGel(TM) Shows 238% Increase in Frequency Of Satisfying Sexual Events, According to Data at ISSWSH LINCOLNSHIRE, Ill., Nov. 1 /PRNewswire-FirstCall/ -- BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced the presentation of new Phase II clinical data on LibiGel(TM) (transdermal testosterone gel) at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting in Atlanta (October 28-31). Results show the ability of LibiGel to significantly increase the number of satisfying sexual events experienced by surgically menopausal women with female sexual dysfunction (FSD). BioSante's Phase II study assessed the safety and efficacy of LibiGel in the treatment of surgically menopausal women with FSD. Results showed that LibiGel 150 mcg per day significantly increased the number of satisfying sexual events by 238 percent versus baseline (from 2.1 events per month at baseline to 7.1 events during month three; p